Nat Clin Pract Gastroenterol Hepatol. 2006;3(5):285-289. In the adult population, eosinophilic esophagitis tends to be chronic, but stable, with no significant effect on morbidity or mortality.

Allergic reactions come in all varieties. One can even trigger a digestive disease called Eosinophilic Esophagitis, which ...

The investigational monoclonal antibody cendakimab significantly improved symptoms and reduced esophageal eosinophils in ...

Eosinophilic esophagitis (EoE) is an allergic inflammatory disorder that affects the esophagus, causing distressing symptoms such as difficulty swallowing in adolescents and adults, and vomiting ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...

Currently the product is in Phase III stage of development for the treatment of Eosinophilic Esophagitis. IRL201104, is ...

EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

The European Medicines Agency has approved Dupixent as the first treatment for eosinophilic esophagitis (EoE) in young children aged one to 11, m ...

Eosinophilic esophagitis is now an established cause of dysphagia. Gastroenterologists should have a high clinical suspicion for this condition if the characteristic clinical and endoscopic ...